CMO
CRBP icon

Covenant Multifamily Offices’s Corbus Pharmaceuticals CRBP Stock Holding History

Covenant Multifamily Offices’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9
Closed -$2K – 161
2019
Q1 		$2K Buy
+9
New +$1.99K ﹤0.01% 212

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Covenant Multifamily Offices's CRBP Position: Q2 2019 in Review

Covenant Multifamily Offices sold out of Corbus Pharmaceuticals (CRBP) in Q2 2019, closing a stake of 9 shares — an estimated $2K sold.

Covenant Multifamily Offices first reported a position in CRBP in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 103 funds tracked by Wall St. Rank hold CRBP as of Q2 2019.

  • Covenant Multifamily Offices reported no remaining Corbus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Covenant Multifamily Offices sold 9 Corbus Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Covenant Multifamily Offices first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Covenant Multifamily Offices's Corbus Pharmaceuticals position peaked at $2K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2019.

Based on Covenant Multifamily Offices's 13F filing for Q2 2019, filed 31 Jul 2019.